Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease

Neuropathology and Applied Neurobiology

Volumn 41, Issue 5, 2015, Pages 631-645

  Llorens, Franc ^a,b   Zafar, Saima ^a   Ansoleaga, Belén ^b,c   Shafiq, Mohsin ^a   Blanco, Rosi ^b,c   Carmona, Marga ^b,c   Grau Rivera, Oriol ^e   Nos, Carlos ^f   Gelpí, Ellen ^e   del Río, José Antonio ^c,d   Zerr, Inga ^a   Ferrer, Isidre ^b,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f General Subdirectorate of Surveillance and Response to Emergencies in Public Health   (Spain)

Author keywords

Cerebrospinal fluid; Creutzfeldt Jakob disease; Disease subtype; Glycogen synthase kinase 3; Prion biomarkers; Prion protein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; PROTEIN 14 3 3; TAU PROTEIN; MAPT PROTEIN, HUMAN; PRION;

ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEATH; DEMENTIA; DOWN REGULATION; HUMAN; HUMAN TISSUE; NEUROPATHOLOGY; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SPORADIC CREUTZFELDT JAKOB DISEASE; ADULT; AGED; BRAIN; CEREBELLUM; CREUTZFELDT JAKOB DISEASE; FEMALE; FRONTAL LOBE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PRION; SYNAPSE;

14-3-3 PROTEINS; ADULT; AGED; ALPHA-SYNUCLEIN; BIOMARKERS; BRAIN; CEREBELLUM; CREUTZFELDT-JAKOB SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PRIONS; SYNAPSES; TAU PROTEINS;

EID: 84949087681     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12175     Document Type: Article

References (45)

1. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89: 1105-1152
2. Head MW, Ironside JW. The contribution of different prion protein types and host polymorphisms to clinicopathological variations in Creutzfeldt-Jakob disease. Rev Med Virol 2012; 22: 214-229
3. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro CJ, Knight RS, Bernheimer H, Cardone F, Delasnerie-Laupretre N, Cuadrado CN, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz BA, Budka H, Laplanche JL, Will RG, Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811-815
4. Ladogana A, Sanchez-Juan P, Mitrova E, Green A, Cuadrado-Corrales N, Sanchez-Valle R, Koscova S, Aguzzi A, Sklaviadis T, Kulczycki J, Gawinecka J, Saiz A, Calero M, van Duijn CM, Pocchiari M, Knight R, Zerr I. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 2009; 256: 1620-1628
5. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000; 54: 1099-1102
6. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008; 213: 315-325
7. Llorens F, Ansoleaga B, Garcia-Esparcia P, Zafar S, Grau-Rivera O, Lopez-Gonzalez I, Blanco R, Carmona M, Yague J, Nos C, Del Rio JA, Gelpi E, Zerr I, Ferrer I. PrP mRNA and protein expression in brain and PrPc in CSF in Creutzfeldt-Jakob disease MM1 and VV2. Prion 2013; 7: 383-393
8. Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M, Ciesielczyk B, Meissner B, Krasnianski A, Bartl M, Heinemann U, Varges D, Eigenbrod S, Kretzschmar HA, Green A, Zerr I. Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol 2006; 6: 35
9. Foote M, Zhou Y. 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol 2012; 3: 152-164
10. Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T, Ikeda K, Takasaki M. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol 2004; 108: 279-286
11. Frost B, Diamond MI. The expanding realm of prion phenomena in neurodegenerative disease. Prion 2009; 3: 74-77
12. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 2010; 30: 4528-4535
13. Wang XF, Dong CF, Zhang J, Wan YZ, Li F, Huang YX, Han L, Shan B, Gao C, Han J, Dong XP. Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro. Mol Cell Biochem 2008; 310: 49-55
14. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128-1132
15. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013; 136 (Pt 4): 1128-1138
16. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012; 485: 651-655
17. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-697
18. Vital A, Canron MH, Gil R, Hauw JJ, Vital C. A sporadic case of Creutzfeldt-Jakob disease with beta-amyloid deposits and alpha-synuclein inclusions. Neuropathology 2007; 27: 273-277
19. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349: 162-166
20. Gawinecka J, Nowak M, Carimalo J, Cardone F, Asif AR, Wemheuer WM, Schulz-Schaeffer WJ, Pocchiari M, Zerr I. Subtype-specific synaptic proteome alterations in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis 2013; 37: 51-61
21. Siso S, Puig B, Varea R, Vidal E, Acin C, Prinz M, Montrasio F, Badiola J, Aguzzi A, Pumarola M, Ferrer I. Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathol 2002; 103: 615-626
22. Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 1996; 25: 821-828
23. Fernandez E, Collins MO, Uren RT, Kopanitsa MV, Komiyama NH, Croning MD, Zografos L, Armstrong JD, Choudhary JS, Grant SG. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol 2009; 5: 269
24. Freixes M, Puig B, Rodriguez A, Torrejon-Escribano B, Blanco R, Ferrer I. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathol 2004; 108: 295-301
25. Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003; 22: 5435-5445
26. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39: 767-778
27. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Forstl H, Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003; 8: 343-347
28. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev 2013; 12: 289-309
29. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008; 104: 1433-1439
30. Gmitterova K, Heinemann U, Bodemer M, Krasnianski A, Meissner B, Kretzschmar HA, Zerr I. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 2009; 30: 1842-1850
31. Shiga Y, Wakabayashi H, Miyazawa K, Kido H, Itoyama Y. 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. J Clin Neurosci 2006; 13: 661-665
32. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Doring F, Hakimi M, Vonsattel JP, Nussbaum R, Trenkwalder C, Schlossmacher MG. alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 2012; 119: 739-746
33. Baxter HC, Liu WG, Forster JL, Aitken A, Fraser JR. Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain. Neuroscience 2002; 109: 5-14
34. Richard M, Biacabe AG, Streichenberger N, Ironside JW, Mohr M, Kopp N, Perret-Liaudet A. Immunohistochemical localization of 14.3.3 zeta protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathol 2003; 105: 296-302
35. Di FG, Giaccone G, Limido L, Mangieri M, Suardi S, Puoti G, Morbin M, Mazzoleni G, Ghetti B, Tagliavini F. The epsilon isoform of 14-3-3 protein is a component of the prion protein amyloid deposits of Gerstmann-Straussler-Scheinker disease. J Neuropathol Exp Neurol 2007; 66: 124-130
36. Shi Q, Song QQ, Sun P, Zhang J, Song J, Chen LN, Xiao K, Wang SB, Zhang YZ, Li GQ, Sheng LJ, Wang BD, Lu MZ, Han J, Dong XP. Infection of prions and treatment of PrP106-126 alter the endogenous status of protein 14-3-3 and trigger the mitochondrial apoptosis possibly via activating Bax pathway. Mol Neurobiol 2014; 49: 840-851
37. Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: implication for alpha-synucleinopathies. FEBS Lett 2007; 581: 4711-4717
38. Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 2008; 67: 402-416
39. Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Haik S, Fociani P, Bugiani O, Tagliavini F. Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging 2008; 29: 1864-1873
40. Lawson VA, Klemm HM, Welton JM, Masters CL, Crouch P, Cappai R, Ciccotosto GD. Gene knockout of tau expression does not contribute to the pathogenesis of prion disease. J Neuropathol Exp Neurol 2011; 70: 1036-1045
41. Wang GR, Shi S, Gao C, Zhang BY, Tian C, Dong CF, Zhou RM, Li XL, Chen C, Han J, Dong XP. Changes of tau profiles in brains of the hamsters infected with scrapie strains 263K or 139 A possibly associated with the alteration of phosphate kinases. BMC Infect Dis 2010; 10: 86
42. Asuni AA, Perry VH, O'Connor V. Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease. Biochem Soc Trans 2010; 38: 545-551
43. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55
44. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 2004; 101: 2173-2178
45. Siman R, Toraskar N, Dang A, McNeil E, McGarvey M, Plaum J, Maloney E, Grady MS. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma 2009; 26: 1867-1877